[go: up one dir, main page]

WO2008107900A3 - Compositions et procédés permettant de moduler une migration cellulaire - Google Patents

Compositions et procédés permettant de moduler une migration cellulaire Download PDF

Info

Publication number
WO2008107900A3
WO2008107900A3 PCT/IL2008/000310 IL2008000310W WO2008107900A3 WO 2008107900 A3 WO2008107900 A3 WO 2008107900A3 IL 2008000310 W IL2008000310 W IL 2008000310W WO 2008107900 A3 WO2008107900 A3 WO 2008107900A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell migration
compositions
methods
modulating cell
tensin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2008/000310
Other languages
English (en)
Other versions
WO2008107900A2 (fr
Inventor
Yosef Yarden
Menachem Katz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of WO2008107900A2 publication Critical patent/WO2008107900A2/fr
Publication of WO2008107900A3 publication Critical patent/WO2008107900A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G01N33/5758—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0631—Mammary cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G01N33/57515—
    • G01N33/57545—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/585—Integrins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé d'induction d'une migration cellulaire. Le procédé comprend la mise en contact de la cellule avec : (a) un agent qui peut réguler de manière positive l'activité et/ou l'expression de cten ; et (b) un agent qui peut réguler de manière négative l'activité et/ou l'expression de la tensine-1 ou de la tensine-3, induisant ainsi la migration cellulaire.
PCT/IL2008/000310 2007-03-07 2008-03-06 Compositions et procédés permettant de moduler une migration cellulaire Ceased WO2008107900A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90529407P 2007-03-07 2007-03-07
US60/905,294 2007-03-07

Publications (2)

Publication Number Publication Date
WO2008107900A2 WO2008107900A2 (fr) 2008-09-12
WO2008107900A3 true WO2008107900A3 (fr) 2009-03-12

Family

ID=39738900

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2008/000310 Ceased WO2008107900A2 (fr) 2007-03-07 2008-03-06 Compositions et procédés permettant de moduler une migration cellulaire

Country Status (1)

Country Link
WO (1) WO2008107900A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004061123A2 (fr) * 2002-12-30 2004-07-22 Exelixis, Inc. Mbcat servant de modificateurs de la voie de beta-catenine et leurs procedes d'utilisation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004061123A2 (fr) * 2002-12-30 2004-07-22 Exelixis, Inc. Mbcat servant de modificateurs de la voie de beta-catenine et leurs procedes d'utilisation

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CHEN HUAIYANG ET AL: "Regulation of tensin-promoted cell migration by its focal adhesion binding and Src homology domain 2.", BIOCHEMICAL JOURNAL, vol. 370, no. 3, 15 March 2003 (2003-03-15), pages 1039 - 1045, XP002496886, ISSN: 0264-6021 *
CHIANG M-K ET AL: "Inactivation of tensin3 in mice results in growth retardation and postnatal lethality", DEVELOPMENTAL BIOLOGY, ACADEMIC PRESS, NEW YORK, NY, US, vol. 279, no. 2, 15 March 2005 (2005-03-15), pages 368 - 377, XP004767097, ISSN: 0012-1606 *
CUI YUMIN ET AL: "Epidermal growth factor modulates tyrosine phosphorylation of a novel tensin family member, tensin3.", MOLECULAR CANCER RESEARCH : MCR APR 2004, vol. 2, no. 4, April 2004 (2004-04-01), pages 225 - 232, XP002496882, ISSN: 1541-7786 *
HAFIZI SASSAN ET AL: "Downregulation of C1-TEN expression in human cancer", FASEB JOURNAL, vol. 21, no. 5, April 2007 (2007-04-01), & EXPERIMENTAL BIOLOGY 2007 ANNUAL MEETING; WASHINGTON, DC, USA; APRIL 28 -MAY 02, 2007, pages A619, XP009106058, ISSN: 0892-6638 *
KATZ MENACHEM ET AL: "A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration", NATURE CELL BIOLOGY, vol. 9, no. 8, August 2007 (2007-08-01), pages 961, XP002496878, ISSN: 1465-7392 *
LO SU HAO ET AL: "Cten, a COOH-terminal tensin-like protein with prostate restricted expression, is down-regulated in prostate cancer.", CANCER RESEARCH 1 AUG 2002, vol. 62, no. 15, 1 August 2002 (2002-08-01), pages 4217 - 4221, XP002496880, ISSN: 0008-5472 *
LO SU HAO: "Tensin.", THE INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY JAN 2004, vol. 36, no. 1, January 2004 (2004-01-01), pages 31 - 34, XP002496881, ISSN: 1357-2725 *
RODRIGUE CHRISTELLE M ET AL: "The cancer chemopreventive agent resveratrol induces tensin, a cell-matrix adhesion protein with signaling and antitumor activities", ONCOGENE, vol. 24, no. 20, May 2005 (2005-05-01), pages 3274 - 3284, XP002496879, ISSN: 0950-9232 *
SASAKI HIDEFUMI ET AL: "Cten mRNA expression is correlated with tumor progression in thymoma.", TUMOR BIOLOGY, vol. 24, no. 5, September 2003 (2003-09-01), pages 271 - 274, XP009106055, ISSN: 1010-4283 *
SASAKI HIDEFUMI ET AL: "Cten mRNA expression was correlated with tumor progression in lung cancers.", LUNG CANCER (AMSTERDAM, NETHERLANDS) MAY 2003, vol. 40, no. 2, May 2003 (2003-05-01), pages 151 - 155, XP009106051, ISSN: 0169-5002 *

Also Published As

Publication number Publication date
WO2008107900A2 (fr) 2008-09-12

Similar Documents

Publication Publication Date Title
WO2010031056A3 (fr) Procédés et compositions pour moduler l'activité ire1, src, et abl
DK2318032T3 (da) Anvendelse af Hsp70 som regulator af enzymatisk aktivitet
WO2009092087A3 (fr) Différenciation, identification et modulation sélectives de cellules th17 humaines
WO2008054676A3 (fr) Dispositifs médicaux et méthodes d'utilisation correspondantes
WO2007067968A3 (fr) Effets d'inhibiteurs de fgfr3 sur la transcription genetique
WO2009007852A3 (fr) Cellules multipotentes/pluripotentes et procédés s'y rapportant
WO2009149956A3 (fr) Protéine de fusion et son utilisation
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
SG170826A1 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
PL1935331T3 (pl) Proces przygotowania elektrod modyfikowanych, elektrod przygotowanych przy pomocy tego procesu i biosensory enzymatyczne zawierające takie elektrody
WO2007149724A3 (fr) Substats destinées à effectuer des réactions d'analyse
WO2010034015A3 (fr) Modulation de la voie de complément alternative
WO2007100901A3 (fr) Schémas posologiques pour l'épinéphrine
WO2008083179A3 (fr) Dispositifs et procédés de surveillance d'analytes
WO2006138418A3 (fr) Amelioration de la performance cognitive avec des activateurs de sirtuine
EP2028503B8 (fr) Procédé pour évaluer l'état de détérioration d'une batterie, dispositif d'évaluation de détérioration et système d'alimentation
WO2009118722A3 (fr) Procédés et compositions pour l’administration orale de protéines
WO2008147536A8 (fr) Procédés et compositions pour accentuer l'activité de protéasome
WO2011062864A3 (fr) Inhibiteurs d'enzymes nox et leurs procédés d'utilisation
WO2005023305A3 (fr) Modulation de l'activite cellulaire au moyen d'un agent diminuant le taux de cholesterol au sein d'une cellule
WO2009117740A3 (fr) Traitement de la dégénérescence du disque intervertébral
NO20060955L (no) Farmasoytisk sammensetning som er nyttig til stamcellemobilisering
BRPI0911556A2 (pt) eletrodo enzimático, e, célula de combustível.
WO2005074655A3 (fr) Materiaux et procede favorisant la regeneration nerveuse
BRPI0719836A2 (pt) Clonagem, expressão e uso de fosfolipases ácidas.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08719935

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08719935

Country of ref document: EP

Kind code of ref document: A2